10 news items
Rhythm Pharmaceuticals Presents Data from Phase 3 Pediatrics Trial at Pediatric Endocrine Society Annual Meeting
RYTM
6 May 24
setmelanotide. Pediatric Population: The prescribing physician should periodically assess response to setmelanotide
Rhythm Pharmaceuticals Announces Publication Of Results From Phase 2 Study Of Setmelanotide For The Treatment Of Hypothalamic Obesity In The Lancet Diabetes & Endocrinology
RYTM
29 Apr 24
achieved a 5% or greater reduction in BMI after 16 weeks of treatment. Hunger was also assessed daily, as self-reported by individual patients
Rhythm Pharmaceuticals Announces Publication of Results from Phase 2 Study of Setmelanotide for the Treatment of Hypothalamic Obesity in The Lancet Diabetes & Endocrinology
RYTM
29 Apr 24
endpoint was the proportion of patients who achieved a 5% or greater reduction in BMI after 16 weeks of treatment. Hunger was also assessed daily, as self
Analyst Expectations For Rhythm Pharmaceuticals's Future
RYTM
26 Apr 24
(NASDAQ:RYTM) in the last three months.
Summarizing their recent assessments, the table
Rhythm Pharmaceuticals to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024
RYTM
24 Apr 24
periodically assess response to setmelanotide therapy. In growing children, the impact of weight loss on growth and maturation should be evaluated
0911agc0suivw9zd1hucca1m3grzgvluhwahgm3rfcta8412csgfseczx
RYTM
16 Apr 24
and discontinue setmelanotide. Pediatric Population: The prescribing physician should periodically assess response to setmelanotide therapy
9ssrcadx g85
RYTM
10 Apr 24
quarter vary from bullish to bearish, as provided by 5 analysts.
Summarizing their recent assessments, the table below illustrates the evolving
ktdvlzjqegv4cmqfqxt227 hli1oxcka1538cfk8bf39z9e
RYTM
11 Mar 24
setmelanotide. Pediatric Population: The prescribing physician should periodically assess response to setmelanotide therapy
bgl1gi1682
RYTM
6 Mar 24
periodically assess response to setmelanotide therapy. In growing children, the impact of weight loss on growth and maturation should be evaluated. In Europe
8a01ptg3wp7kpmemn2mnutsi4im5m4pm6ryjkyd
RYTM
22 Feb 24
. Pediatric Population: The prescribing physician should periodically assess response to setmelanotide therapy. In growing children
- Prev
- 1
- Next